6 Analysts Assess Alkermes: What You Need To Know
Alkermes (NASDAQ:ALKS) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 1 | 4 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 2 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $36.33, a high estimate of $48.00, and a low estimate of $31.00. This current average has increased by 0.92% from the previous average price target of $36.00.
Exploring Analyst Ratings: An In-Depth Overview
A clear picture of Alkermes's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jessica Fye | JP Morgan | Lowers | Neutral | $31.00 | $32.00 |
| Joseph Thome | TD Cowen | Announces | Buy | $34.00 | - |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Neutral | $35.00 | $35.00 |
| Charles Duncan | Cantor Fitzgerald | Raises | Overweight | $48.00 | $43.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Neutral | $35.00 | $35.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Neutral | $35.00 | $35.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Alkermes. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alkermes compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Alkermes's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Alkermes's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Alkermes analyst ratings.
All You Need to Know About Alkermes
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Financial Insights: Alkermes
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Alkermes's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 21.83%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Alkermes's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.51% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.0%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Alkermes's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.73% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Alkermes's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.29.
How Are Analyst Ratings Determined?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.